PFE--

pfe buy of seagen write off pfizer sigvie trial results

$PFE Someone brought up a point on another PFE board... Is pfe’s buy of Seagen now a write-off? Mike said: When reviewing the failed SigVie-002 trial, two-thirds of patients were second-line, meaning they had only failed one treatment before. In that group, the drug showed strong results and a meaningful survival benefit. This means it works as Pfizer's scientists expected—it just couldn't beat the resistance in later-stage, third- and fourth-line patients, i.e. terminal patients.

Comments



No comments

No comments yet

Disclaimer: The above is a summary showing certain market information. Ainvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing, All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market.Report an Issue